Cargando…
Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138405/ https://www.ncbi.nlm.nih.gov/pubmed/35625841 http://dx.doi.org/10.3390/biomedicines10051105 |
_version_ | 1784714617319063552 |
---|---|
author | Godoy-Corchuelo, Juan Miguel Fernández-Beltrán, Luis C. Ali, Zeinab Gil-Moreno, María J. López-Carbonero, Juan I. Guerrero-Sola, Antonio Larrad-Sainz, Angélica Matias-Guiu, Jorge Matias-Guiu, Jordi A. Cunningham, Thomas J. Corrochano, Silvia |
author_facet | Godoy-Corchuelo, Juan Miguel Fernández-Beltrán, Luis C. Ali, Zeinab Gil-Moreno, María J. López-Carbonero, Juan I. Guerrero-Sola, Antonio Larrad-Sainz, Angélica Matias-Guiu, Jorge Matias-Guiu, Jordi A. Cunningham, Thomas J. Corrochano, Silvia |
author_sort | Godoy-Corchuelo, Juan Miguel |
collection | PubMed |
description | There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with the progression of the disease but also years before diagnosis. Still, there are some discrepancies in findings relating to the causal nature of lipid metabolic alterations, partly due to the great clinical heterogeneity in ALS. ALS presentation is within a disorder spectrum with Frontotemporal Dementia (FTD), and many patients present mixed forms of ALS and FTD, thus increasing the variability. Lipid metabolic and other systemic metabolic alterations have not been well studied in FTD, or in ALS–FTD mixed forms, as has been in pure ALS. With the recent development in lipidomics and the integration with other -omics platforms, there is now emerging data that not only facilitates the identification of biomarkers but also enables understanding of the underlying pathological mechanisms. Here, we reviewed the recent literature to compile lipid metabolic alterations in ALS, FTD, and intermediate mixed forms, with a view to appraising key commonalities or differences within the spectrum. |
format | Online Article Text |
id | pubmed-9138405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91384052022-05-28 Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders Godoy-Corchuelo, Juan Miguel Fernández-Beltrán, Luis C. Ali, Zeinab Gil-Moreno, María J. López-Carbonero, Juan I. Guerrero-Sola, Antonio Larrad-Sainz, Angélica Matias-Guiu, Jorge Matias-Guiu, Jordi A. Cunningham, Thomas J. Corrochano, Silvia Biomedicines Review There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with the progression of the disease but also years before diagnosis. Still, there are some discrepancies in findings relating to the causal nature of lipid metabolic alterations, partly due to the great clinical heterogeneity in ALS. ALS presentation is within a disorder spectrum with Frontotemporal Dementia (FTD), and many patients present mixed forms of ALS and FTD, thus increasing the variability. Lipid metabolic and other systemic metabolic alterations have not been well studied in FTD, or in ALS–FTD mixed forms, as has been in pure ALS. With the recent development in lipidomics and the integration with other -omics platforms, there is now emerging data that not only facilitates the identification of biomarkers but also enables understanding of the underlying pathological mechanisms. Here, we reviewed the recent literature to compile lipid metabolic alterations in ALS, FTD, and intermediate mixed forms, with a view to appraising key commonalities or differences within the spectrum. MDPI 2022-05-10 /pmc/articles/PMC9138405/ /pubmed/35625841 http://dx.doi.org/10.3390/biomedicines10051105 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Godoy-Corchuelo, Juan Miguel Fernández-Beltrán, Luis C. Ali, Zeinab Gil-Moreno, María J. López-Carbonero, Juan I. Guerrero-Sola, Antonio Larrad-Sainz, Angélica Matias-Guiu, Jorge Matias-Guiu, Jordi A. Cunningham, Thomas J. Corrochano, Silvia Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title | Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title_full | Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title_fullStr | Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title_full_unstemmed | Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title_short | Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders |
title_sort | lipid metabolic alterations in the als–ftd spectrum of disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138405/ https://www.ncbi.nlm.nih.gov/pubmed/35625841 http://dx.doi.org/10.3390/biomedicines10051105 |
work_keys_str_mv | AT godoycorchuelojuanmiguel lipidmetabolicalterationsinthealsftdspectrumofdisorders AT fernandezbeltranluisc lipidmetabolicalterationsinthealsftdspectrumofdisorders AT alizeinab lipidmetabolicalterationsinthealsftdspectrumofdisorders AT gilmorenomariaj lipidmetabolicalterationsinthealsftdspectrumofdisorders AT lopezcarbonerojuani lipidmetabolicalterationsinthealsftdspectrumofdisorders AT guerrerosolaantonio lipidmetabolicalterationsinthealsftdspectrumofdisorders AT larradsainzangelica lipidmetabolicalterationsinthealsftdspectrumofdisorders AT matiasguiujorge lipidmetabolicalterationsinthealsftdspectrumofdisorders AT matiasguiujordia lipidmetabolicalterationsinthealsftdspectrumofdisorders AT cunninghamthomasj lipidmetabolicalterationsinthealsftdspectrumofdisorders AT corrochanosilvia lipidmetabolicalterationsinthealsftdspectrumofdisorders |